Abstract
In a prospective, randomized, double-blind study, the effect of ciprofloxacin (250 mg orally, twice daily) was compared with that of trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally, twice daily) on 45 patients with complicated urinary tract infections. Pretherapy isolates were all members of the family Enterobacteriaceae. Isolates were eradicated from 18 (82%) of 22 patients treated with ciprofloxacin and 12 (52%) of 23 patients treated with trimethoprim-sulfamethoxazole during and 5 to 9 days after therapy (P = 0.035). Both groups had similar relapse and reinfection rates at 4 to 6 weeks posttherapy. Adverse effects were mild and reversible, occurring in 1 of 22 in the ciprofloxacin group and 6 of 23 in the trimethoprim-sulfamethoxazole group. Disk diffusion susceptibility tests correlated better with broth macrodilution for ciprofloxacin than for trimethoprim-sulfamethoxazole. Ciprofloxacin is a safe, effective alternative to trimethoprim-sulfamethoxazole for the treatment of complicated urinary tract infections.
Full text
PDF![1327](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae73/175861/e64fd6cac63f/aac00088-0057.png)
![1328](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae73/175861/4745167450b4/aac00088-0058.png)
![1329](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae73/175861/3beff90b01eb/aac00088-0059.png)
![1330](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae73/175861/18976c076c69/aac00088-0060.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boerema J. B., Dalhoff A., Debruyne F. M. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31(1):13–18. doi: 10.1159/000238308. [DOI] [PubMed] [Google Scholar]
- Boerema J., Boll B., Muytjens H., Branolte J. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother. 1985 Aug;16(2):211–217. doi: 10.1093/jac/16.2.211. [DOI] [PubMed] [Google Scholar]
- Boscia J. A., Kobasa W. D., Knight R. A., Abrutyn E., Levison M. E., Kaye D. Epidemiology of bacteriuria in an elderly ambulatory population. Am J Med. 1986 Feb;80(2):208–214. doi: 10.1016/0002-9343(86)90011-2. [DOI] [PubMed] [Google Scholar]
- Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dan M., Golomb J., Gorea A., Braf Z., Berger S. A. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother. 1986 Jul;30(1):88–89. doi: 10.1128/aac.30.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davis R. L., Koup J. R., Williams-Warren J., Weber A., Smith A. L. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother. 1985 Jul;28(1):74–77. doi: 10.1128/aac.28.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gargan R. A., Brumfitt W., Hamilton-Miller J. M. Antibody-coated bacteria in urine: criterion for a positive test and its value in defining a higher risk of treatment failure. Lancet. 1983 Sep 24;2(8352):704–706. doi: 10.1016/s0140-6736(83)92247-x. [DOI] [PubMed] [Google Scholar]
- Gleckman R., Crowley M., Natsios G. A. Therapy of recurrent invasive urinary-tract infections of men. N Engl J Med. 1979 Oct 18;301(16):878–880. doi: 10.1056/NEJM197910183011607. [DOI] [PubMed] [Google Scholar]
- Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joos B., Ledergerber B., Flepp M., Bettex J. D., Lüthy R., Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985 Mar;27(3):353–356. doi: 10.1128/aac.27.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaye D. Urinary tract infections in the elderly. Bull N Y Acad Med. 1980 Mar;56(2):209–220. [PMC free article] [PubMed] [Google Scholar]
- Preheim L. C., Cuevas T. A., Roccaforte J. S., Mellencamp M. A., Bittner M. J. Ciprofloxacin and antacids. Lancet. 1986 Jul 5;2(8497):48–48. doi: 10.1016/s0140-6736(86)92596-1. [DOI] [PubMed] [Google Scholar]
- Preheim L. C., Cuevas T. A., Roccaforte J. S., Mellencamp M. A., Bittner M. J. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. Am J Med. 1987 Apr 27;82(4A):295–300. [PubMed] [Google Scholar]
- Sabbaj J., Hoagland V. L., Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis Suppl. 1986;48:48–53. [PubMed] [Google Scholar]
- Sheldon C. A., Gonzalez R. Differentiation of upper and lower urinary tract infections: how and when? Med Clin North Am. 1984 Mar;68(2):321–333. doi: 10.1016/s0025-7125(16)31133-6. [DOI] [PubMed] [Google Scholar]
- Smith J. W., Jones S. R., Reed W. P., Tice A. D., Deupree R. H., Kaijser B. Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med. 1979 Oct;91(4):544–548. doi: 10.7326/0003-4819-91-4-544. [DOI] [PubMed] [Google Scholar]
- Vellucci A., Bernardini G., Battaglia A. M., Battaglia P. Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections. Int J Clin Pharmacol Ther Toxicol. 1987 May;25(5):279–281. [PubMed] [Google Scholar]